NVO
Novo Nordisk A/S
$60.71
-$0.69(-1.12%)
48
Overall
60
Value
36
Tech
--
Quality
Market Cap
$255.40B
Volume
10.69M
52W Range
$45.05 - $127.61
Target Price
$65.88
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $107.9B | $111.8B | $111.7B | $111.8B | $122.0B | $126.9B | $340.2B | $177.0B | $232.3B | $290.4B | ||
| Total Revenue | $107.9B | $111.8B | $111.7B | $111.8B | $122.0B | $126.9B | $140.8B | $177.0B | $232.3B | $290.4B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $16.2B | $17.2B | $17.6B | $17.6B | $20.1B | $20.9B | $-23.7B | $28.4B | $35.8B | $44.5B | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $91.7B | $94.6B | $94.1B | $94.2B | $101.9B | $106.0B | $117.1B | $148.5B | $196.5B | $245.9B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $45.8B | $46.9B | $46.1B | $48.1B | $50.0B | $51.9B | $-58.5B | $74.7B | $93.9B | $117.5B | ||
| Research & Development | $13.6B | $14.6B | $14.0B | $14.8B | $14.2B | $7.4B | $17.8B | $5.5B | $32.4B | $48.1B | ||
| Research Expense | $13.6B | $14.6B | $14.0B | $14.8B | $14.2B | $7.4B | -- | $5.5B | $32.4B | $48.1B | ||
| Selling, General & Administrative | $32.2B | $32.3B | $32.1B | $33.3B | $35.8B | $36.9B | $-41.1B | $50.7B | $61.6B | $67.4B | ||
| Selling & Marketing Expenses | $28.3B | $28.4B | $28.3B | $29.4B | $31.8B | $32.9B | $-37.0B | $46.2B | $56.7B | $62.1B | ||
| General & Administrative Expenses | $3.9B | $4.0B | $3.8B | $3.9B | $4.0B | $4.0B | $4.0B | $4.5B | $4.9B | $5.3B | ||
| Salaries & Wages | -- | -- | -- | -- | -- | $6.3B | -- | $10.0B | $12.4B | -- | ||
| Depreciation & Amortization | -- | -- | -- | -- | -- | $1.7B | -- | $2.3B | $3.1B | -- | ||
| Depreciation & Amortization | -- | -- | -- | -- | -- | $1.7B | -- | $2.3B | $3.1B | -- | ||
| Amortization | -- | -- | -- | -- | -- | $1.0B | -- | $1.4B | $1.8B | -- | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | $-460.0M | $332.0M | $6.3B | $-119.0M | $2.1B | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $46.0B | $47.7B | $47.9B | $46.1B | $51.9B | $54.1B | $58.6B | $73.8B | $102.6B | $128.3B | ||
| EBITDA | -- | -- | -- | -- | -- | -- | $65.4B | $76.8B | $114.9B | $148.3B | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $6.0B | $726.0M | $1.5B | $1.8B | $4.0B | $2.6B | $-289.0M | $3.0B | $845.0M | $2.0B | ||
| Interest Income Operating | $3.5B | $737.0M | $1.0B | $1.2B | $600.0M | -- | -- | -- | -- | -- | ||
| Intinc | $85.0M | $92.0M | $1.2B | $2.1B | $65.0M | $337.0M | $231.0M | $-239.0M | $2.9B | $6.2B | ||
| Net Non-Operating Interest Income/Expense | $-6.0B | $-634.0M | $-287.0M | $367.0M | $-3.9B | $-2.3B | $-180.0M | $-3.2B | $2.1B | $4.2B | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | -- | $640.0M | $-124.0M | $37.0M | -- | ||
| Other Income/Expense | -- | -- | -- | -- | -- | -- | $-616.0M | $-910.0M | $1.8B | -- | ||
| Other Special Charges | -- | -- | -- | -- | -- | -- | $16.6B | $1.0B | -- | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | $2.5B | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | -- | -- | -- | -- | -- | -- | $59.4B | $69.4B | $105.5B | $129.2B | ||
| Pre-Tax Income | $43.5B | $47.8B | $48.7B | $47.6B | $48.6B | $53.0B | $59.1B | $68.6B | $104.7B | $127.2B | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $8.6B | $9.9B | $10.6B | $9.0B | $9.6B | $11.0B | $11.3B | $13.5B | $21.0B | $26.2B | ||
| NET INCOME | ||||||||||||
| Net Income | $34.9B | $37.9B | $38.1B | $38.6B | $39.0B | $42.0B | $47.8B | $55.0B | $83.7B | $101.0B | ||
| Net Income (Continuing Operations) | $34.9B | $37.9B | $38.1B | $38.6B | $39.0B | $42.0B | $47.8B | $55.0B | $83.7B | $101.0B | ||
| Net Income (Discontinued Operations) | $34.9B | $37.9B | $38.1B | $38.6B | $39.0B | $42.0B | $47.8B | $55.0B | $83.7B | $101.0B | ||
| Net Income (Common Stockholders) | $34.9B | $37.9B | $38.1B | $38.6B | $39.0B | $42.0B | $47.8B | $55.0B | $83.7B | $101.0B | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | $76.9B | $125.9B | ||
| TOTALS | ||||||||||||
| Total Expenses | -- | -- | -- | -- | -- | -- | $37.6B | $103.2B | $129.7B | $162.1B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | -- | -- | -- | -- | -- | $2.3K | $4.6B | $4.5B | $4.5B | $4.5B | ||
| Average Shares Outstanding (Diluted) | -- | -- | -- | -- | -- | $2.3K | $4.6B | $4.5B | $4.5B | $4.5B | ||
| Shares Outstanding | $3.4B | $3.4B | $3.4B | $3.4B | $3.4B | $3.4B | $4620000.0B | $2280000.0B | $3.4B | $3.4B | ||
| Basic EPS | $13.56 | $14.99 | $15.42 | $15.96 | $16.41 | $18.05 | $10.4 | $12.26 | $18.67 | $22.67 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $18.05 | -- | $12.26 | $18.67 | $22.67 | ||
| Diluted EPS | $13.52 | $14.96 | $15.39 | $15.93 | $16.38 | $18.01 | $10.37 | $12.22 | $18.62 | $22.63 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $18.01 | -- | $12.22 | $18.62 | $22.63 | ||
| Dividend Per Share | -- | -- | -- | -- | -- | $9.1 | $5.2 | -- | $9.4 | $11.4 | ||
| OTHER METRICS | ||||||||||||
| Earnings from equity interest | -- | -- | -- | -- | -- | -- | $-24.0M | $-189.0M | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | -- | -- | $-24.0M | $-189.0M | -- | -- | ||
| Other Costof Revenue | -- | -- | -- | -- | -- | -- | -- | $28.4B | $35.8B | $44.5B | ||
| Other Gand A | $3.9B | $4.0B | $3.8B | $3.9B | $4.0B | $4.0B | $4.0B | $4.5B | $4.9B | $5.3B | ||
| Restruct | -- | -- | -- | -- | -- | -- | $2.5B | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NVO | $60.71 | -1.1% | 10.69M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |